Agriflu (trivalent influenza virus vaccine) / CSL Behring - LARVOL DELTA

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers (clinicaltrials.gov) - P1 | N=130 | Completed | Sponsor: Roswell Park Cancer Institute | Phase classification: P4 ➔ P1

Phase classification • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Myelodysplastic Syndrome • Oncology • Respiratory Diseases

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers (clinicaltrials.gov) - P4 | N=130 | Completed | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Completed | N=200 ➔ 130 | Trial completion date: Mar 2026 ➔ Jun 2022 | Trial primary completion date: Apr 2025 ➔ Jun 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Myelodysplastic Syndrome • Oncology • Respiratory Diseases

PERIOP-04: Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Ottawa Hospital Research Institute | Recruiting ➔ Completed | Trial completion date: Jul 2021 ➔ Oct 2022 | Trial primary completion date: Jul 2021 ➔ Sep 2022

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Oncology • Respiratory Diseases

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months (clinicaltrials.gov) - P3 | N=676 | Completed | Sponsor: SK Bioscience Co., Ltd. | Not yet recruiting ➔ Completed

Preclinical • Trial completion • Infectious Disease • Respiratory Diseases

Pre-existing helminth infection impairs the efficacy of adjuvanted influenza vaccination in mice. (PubMed, PLoS One) - "We either introduced a prime-boost vaccination regimen using the non-adjuvanted anti-influenza vaccine Begripal or employed the adjuvanted influenza vaccine Fluad...In summary we demonstrate that basic improvements of influenza vaccination regimen are not sufficient to confer sterile immunity on the background of helminth-induced immunosuppression, despite amelioration of pathology i.e. weight loss. Our findings highlight the risk of failed vaccinations in helminth-endemic areas, especially in light of the ongoing vaccination campaign to control the COVID-19 pandemic."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Combination of Deworming and Prime-Boost Vaccination Regimen Restores Efficacy of Vaccination Against Influenza in Helminth-Infected Mice. (PubMed, Front Immunol) - "Two injections with the non-adjuvanted anti-influenza vaccine Begripal conferred 60% protection while MF59-adjuvanted Fluad conferred 100% protection from a 2009 pH1N1 infection in FBZ-treated, formerly L. sigmodontis-infected mice. Of note, applying this improved prime-boost regimen did not restore protection in untreated L. sigmodontis-infected mice. In summary our findings highlight the risk of failed vaccinations due to helminth infection."

Journal • Preclinical • Immune Modulation • Immunology • Infectious Disease • Inflammation • Respiratory Diseases

"Mir wurde gerade diese #Werbung gezeigt, die sich dafür Stark macht trotz Krankheitssymptomen "da zu sein". Ich finde diese Werbung für #BoxaGrippal in der momentanen Lage sehr unpassend @BoehringerDE! https://t.co/0rBh72acJ5" (@newventureman)

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - P=N/A; N=55; Completed; Sponsor: Wake Forest University Health Sciences; Active, not recruiting ➔ Completed

Clinical • Trial completion • Astrocytoma • Brain Cancer • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - P=N/A; N=55; Active, not recruiting; Sponsor: Wake Forest University Health Sciences; Trial completion date: Jul 2021 ➔ Oct 2021

Clinical • Trial completion date • Astrocytoma • Brain Cancer • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - P=N/A; N=55; Active, not recruiting; Sponsor: Wake Forest University Health Sciences; Trial completion date: Apr 2021 ➔ Jul 2021

Clinical • Trial completion date • Astrocytoma • Brain Cancer • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers (clinicaltrials.gov) - P4; N=200; Recruiting; Sponsor: Roswell Park Cancer Institute; Trial completion date: Mar 2022 ➔ Mar 2026; Trial primary completion date: Mar 2021 ➔ Apr 2025

Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Respiratory Diseases

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers (clinicaltrials.gov) - P4; N=200; Recruiting; Sponsor: Roswell Park Cancer Institute; Phase classification: P=N/A ➔ P4; Trial completion date: Oct 2021 ➔ Feb 2022

Clinical • Phase classification • Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Respiratory Diseases

PERIOP-04: Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Ottawa Hospital Research Institute; Trial completion date: Jan 2020 ➔ Jul 2021; Trial primary completion date: Jan 2020 ➔ Jul 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Oncology • Respiratory Diseases

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - P=N/A; N=55; Active, not recruiting; Sponsor: Wake Forest University Health Sciences; Trial completion date: Dec 2020 ➔ Apr 2021; Trial primary completion date: Apr 2019 ➔ Jan 2020

Clinical • Trial completion date • Trial primary completion date • Astrocytoma • Brain Cancer • Glioma • Oncology • Solid Tumor

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers (clinicaltrials.gov) - P=N/A; N=200; Recruiting; Sponsor: Roswell Park Cancer Institute; Trial primary completion date: Oct 2020 ➔ Jan 2021

Clinical • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Respiratory Diseases

Influenza vaccine for 2020-2021. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease